Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study

Saved in:
Bibliographic Details
Published in:Translational lung cancer research 2023-11, Vol.12 (11), p.2229-2244
Main Authors: Zhang, Dongming, Liu, Xiaoyan, Shen, Fangfang, Zhao, Dahai, Shi, Yuequan, Zhang, Haoran, Liu, Jia, Gao, Xiaoxing, Chen, Minjiang, Zhao, Jing, Zhong, Wei, Gao, Junzhen, He, Min, Liu, Yonggang, Yang, Xiaoling, Qin, Jianwen, Tang, Yuling, Mu, Xinlin, Gu, Yangchun, Zhang, Shucai, Chen, Xueqin, Pang, Li, Meng, Qingwei, Guo, Ye, Zhang, Yuhui, Li, Wei, Xing, Puyuan, Cheng, Yuan, Xin, Tao, Li, Qingxia, Li, Yu, Chen, Jun, Gao, Feng, Jin, Bo, Rossi, Antonio, Adachi, Hiroyuki, Guerrera, Francesco, Husain, Hatim, Xu, Yan, Wang, Mengzhao
Format: Article
Language:English
Subjects:
Original
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2218-6751
2226-4477
DOI:10.21037/tlcr-23-577